Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Ten Ways Degraders Differentiate from Traditional Small Molecules
ARV-766
ARV-766|CAS 2750830-09-0 |DC Chemicals
AUA 2024: ARV-766, a PROTAC Androgen Receptor Degrader, Combined with ...
ARV-766 | Excenen PharmaTech
ARV-766 합성법과 임상 시험에 관한 고찰
Luxdegalutamide | Androgen Receptor | PROTACs | TargetMol
ARV-766 | AR PROTAC | Probechem Biochemicals
ASCO 2024: ARV-766, a PROTAC Androgen Receptor Degrader, in mCRPC ...
ARV766结构的3处改变使其优先被考虑推至3期临床 - 药时代DrugTimes
ARV-766 (Luxdegalutamide) | CAS 2750830-09-0 | AbMole BioScience | ARV ...
ARV-766 CAS#: 2504913-62-4
Insight into Recent Advances in Degrading Androgen Receptor for ...
诺华超10亿美元囊获Arvinas潜在“best-in-class”蛋白降解剂！
ARV-766 | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
2023AACR | 首次公开新药结构点评_药智新闻
Luxdegalutamide (ARV-766) | Androgen Receptor PROTAC Degrader | CAS ...
ARV-771 is a potent pan-BET degrader. (A) Chemical structures of ...
PROTAC先锋--Arvinas：公布ARV-766的1/2期试验的最新积极数据_腾讯新闻
ARV766结构的3处改变使其优先被考虑推至3期临床 - 知乎
MP14-19: ARV-766, a PROTAC androgen receptor (AR) degrader, combined ...
ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR ...
Abstract ND03: Discovery of ARV-766, an androgen receptor degrading ...
Arvinas and Novartis to Develop and Commercialize PROTAC® Androgen ...
An Update on Clinically Advanced PROTAC Degraders and Their Synthesis
The potential role of ARV-766, an oral PROTAC AR degrader, in mCRPC ...
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active ...
ARV-766, an oral AR degrading PROTAC that targets wild-type and ...
Disclosed structures of PROTACs advanced into clinical investigations ...
PROTAC-induced BET protein degradation as a therapy for castration ...
ARV-766 shows promising efficacy and tolerability in mCRPC | Urology ...
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative ...
PROTAC降伏雄激素受体 - 知乎
前列腺癌治疗新思路：用PROTAC降伏雄激素受体！_药智新闻
(A) Structures of ARV-110 and ARV-471. (B) Structures of commonly used ...
PROTAC Androgen receptor degrader-1 | Androgen Receptor Degrader ...
Current strategies for the design of PROTAC linkers: a critical review
ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC
诺华重金押注的 AR PROTAC 国内申报临床！近 20 家本土药企在研
Arvinas Enters into a Transaction with Novartis, including a Global ...
CRBN配体的作用和最新进展 - 药时代DrugTimes
arvn-20231231
ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic ...
ARV-766 shows promising efficacy and tolerability in mCRPC | Urology Times
Luxdegalutamide (ARV-766) | PROTAC | MedChemExpress
ARV-766是一种口服活性强的蛋白水解靶向嵌合体(PROTAC)蛋白降解剂 - ChemicalBook
ARD-266 | PROTAC Androgen Receptor Degrader | MedChemExpress
Strategies for the discovery of oral PROTAC degraders aimed at cancer ...
Putative binding modes of clinical PROTACS - Think Molecular
Journal of Medicinal Chemistry | Vol 65, No 24
诺华超10亿美元囊获Arvinas潜在“best-in-class”蛋白降解剂！_腾讯新闻
ARV-110 is an Orally Active, Specific Androgen Receptor (AR) PROTAC ...
BRD4新型强效蛋白水解靶向嵌合体（PROTAC）降解剂的结构引导发现,Bioorganic Chemistry - X-MOL
ARV766结构的3处改变使其优先被考虑推至3期临床_手机新浪网
速递！Arvinas多款明星PROTAC一览 - 知乎
Arvinas公布AR PROTAC药物ARV-766积极数据医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
A molecule inducing androgen receptor degradation and selectively ...
Androgen receptor degrader-4 | TargetMol
ARV-766 shows promising efficacy and tolerability in mCRPC
ARV-766: A Promising PROTAC for Overcoming Resistance in Advanced ...
ARV-766 PROTAC: first results will be... - Advanced Prostate...
不亲临现场，如何了解AACR的最新研究进展？ - 知乎
ARV766结构的3处改变使其优先被考虑推至3期临床 | 药时代DrugTimes
ASCO 2024: ARV-766在去势抵抗性前列腺癌的1/2期研究初步结果
Frontiers | Androgen Receptor-Directed Molecular Conjugates for ...
PROTAC Degraders of Androgen Receptor‐Integrated Dissolving ...
An innovative PROTAC, ARV-825, which links BRD4 to E3 ubiquitin ligase ...
医药魔方
